Annals of Oncology 12:887-894, 2001
© 2001 European Society for Medical Oncology
review-article |
Surgical management of hepatic metastases from colorectal malignancies
Department of digesive surgery, Ambroise—Paré Hospital Boulogne, France
B. Nordlinger, MD Department of digestive surgery Ambroise-Paré Hospital 9, avenue du Général de Gaulle 92100 Boulogne France E-mail bernard.nordiinger{at}apr.ap-hop-paris.fr
Liver metastasis represents the major cause of death of patients who have been treated for colorectal adenocarcinoma. Spontaneous survival rarely exceeds two years. Surgery can offer long-term survival and resection should be considered when liver metastases can be totally resected with clear margins and when there is no non-resectable extra-hepatic disease. The choice between anatomical or wedge resection depends on the number and the location of the metastases btit does not influence survival. Clamping methods limit blood loss. Operative mortality is generally less than 5%. The five-year survival rate after surgical resection varies from 20% to 45% according to several prognostic factors. The longer survival is observed in patients with fewer than four lesions, with lesions smaller than 4 cm, without extra-hepatic disease, with lesions that appeared more than two years after the resection of a stage I or II colorectal cancer and whose CEA level is normal. After resection, follow-tip can detect hepatic recurrence that can be treated with repeat hepatectomy. The efficacy of systemic chemotherapy using new agents can increase the number of patients amenable to surgery. Regional therapies with cryo therapy or radiofrequency ablation can help to treat unresect able or non-totally resectable lesions and may improve survival. The effects on survival of adjuvant treatments, including preor postoperative systemic or postoperative intra-arterial chemotherapy, are currently under evaluation.
adjuvant chemotherapy, colorectal cancer, liver metastases, surgery
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Ychou, W. Hohenberger, S. Thezenas, M. Navarro, J. Maurel, C. Bokemeyer, E. Shacham-Shmueli, F. Rivera, C. Kwok-Keung Choi, and A. Santoro A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer Ann. Onc., December 1, 2009; 20(12): 1964 - 1970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. PILATI, E. MAMMANO, S. MOCELLIN, E. TESSARI, M. LISE, and D. NITTI Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases Combined or Not with Systemic Chemotherapy Anticancer Res, October 1, 2009; 29(10): 4139 - 4144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Rahman, J. Evans, G. J. Toogood, P. A. Lodge, and K. R. Prasad Prognostic Utility of Postoperative C-reactive Protein for Posthepatectomy Liver Failure Arch Surg, March 1, 2008; 143(3): 247 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mocellin, P. Pilati, M. Lise, and D. Nitti Meta-Analysis of Hepatic Arterial Infusion for Unresectable Liver Metastases From Colorectal Cancer: The End of an Era? J. Clin. Oncol., December 10, 2007; 25(35): 5649 - 5654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D.W. van der Bilt, M. E. Soeters, A. M.M.J. Duyverman, M. W. Nijkamp, P. O. Witteveen, P. J. van Diest, O. Kranenburg, and I. H.M. Borel Rinkes Perinecrotic Hypoxia Contributes to Ischemia/Reperfusion-Accelerated Outgrowth of Colorectal Micrometastases Am. J. Pathol., April 1, 2007; 170(4): 1379 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lejeune, M. J. Bismuth, T. Conroy, C. Zanni, P. Bey, L. Bedenne, J. Faivre, P. Arveux, and F. Guillemin Use of a Decision Analysis Model to Assess the Cost-Effectiveness of 18F-FDG PET in the Management of Metachronous Liver Metastases of Colorectal Cancer J. Nucl. Med., December 1, 2005; 46(12): 2020 - 2028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Haaga, A. A. Exner, Y. Wang, N. T. Stowe, and P. J. Tarcha Combined Tumor Therapy by Using Radiofrequency Ablation and 5-FU-Laden Polymer Implants: Evaluation in Rats and Rabbits Radiology, December 1, 2005; 237(3): 911 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Poston, R. Adam, S. Alberts, S. Curley, J. Figueras, D. Haller, F. Kunstlinger, G. Mentha, B. Nordlinger, Y. Patt, et al. OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer J. Clin. Oncol., October 1, 2005; 23(28): 7125 - 7134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rubbia-Brandt, V. Audard, P. Sartoretti, A. D. Roth, C. Brezault, M. Le Charpentier, B. Dousset, P. Morel, O. Soubrane, S. Chaussade, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Ann. Onc., March 1, 2004; 15(3): 460 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ercolani, G. L. Grazi, M. Ravaioli, M. Cescon, A. Gardini, G. Varotti, M. Del Gaudio, B. Nardo, and A. Cavallari Liver Resection for Multiple Colorectal Metastases: Influence of Parenchymal Involvement and Total Tumor Volume, vs Number or Location, on Long-term Survival Arch Surg, October 1, 2002; 137(10): 1187 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Lawes and P B Boulos Advances in the management of rectal cancer J R Soc Med, January 12, 2002; 95(12): 587 - 590. [Full Text] [PDF]
|
|